160 related articles for article (PubMed ID: 23647051)
1. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
Bose P; Simmons GL; Grant S
Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker SR; Mallinger A; Workman P; Clarke PA
Pharmacol Ther; 2017 May; 173():83-105. PubMed ID: 28174091
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.
Johnson N; Shapiro GI
Expert Opin Ther Targets; 2010 Nov; 14(11):1199-212. PubMed ID: 20932174
[TBL] [Abstract][Full Text] [Related]
4. Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy.
Zheng M; Zhang XY; Chen W; Xia F; Yang H; Yuan K; Yang P
Future Med Chem; 2024 Feb; 16(4):369-388. PubMed ID: 38288571
[TBL] [Abstract][Full Text] [Related]
5. A systematic review on understanding the mechanistic pathways and clinical aspects of natural CDK inhibitors on cancer progression.: Unlocking cellular and biochemical mechanisms.
Asghar A; Chohan TA; Khurshid U; Saleem H; Mustafa MW; Khursheed A; Alafnan A; Batul R; Bin Break MK; Almansour K; Anwar S
Chem Biol Interact; 2024 Apr; 393():110940. PubMed ID: 38467339
[TBL] [Abstract][Full Text] [Related]
6. Clonal Evolution of B-Cell Acute Lymphoblastic Leukemia with del(9)(p13p21) into Mixed Phenotype Acute Leukemia Presenting as an Isolated Testicular Relapse.
Miller LH; Park SI; Saxe D; Lew G; Raikar SS
Reports (MDPI); 2019 Sep; 2(3):. PubMed ID: 38370916
[TBL] [Abstract][Full Text] [Related]
7. The Role of CD4/6 Inhibitors in Breast Cancer Treatment.
Purohit L; Jones C; Gonzalez T; Castrellon A; Hussein A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279242
[TBL] [Abstract][Full Text] [Related]
8. PIK Your Poison: The Effects of Combining PI3K and CDK Inhibitors against Metastatic Cutaneous Squamous Cell Carcinoma In Vitro.
Perry JR; Genenger B; Thind AS; Ashford B; Ranson M
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254859
[TBL] [Abstract][Full Text] [Related]
9. Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent.
Chinyama HA; Wei L; Mokgautsi N; Lawal B; Wu ATH; Huang HS
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003585
[TBL] [Abstract][Full Text] [Related]
10.
Yu Y; Cao WM; Cheng F; Shi Z; Han L; Yi JL; da Silva EM; Dopeso H; Chen H; Yang J; Wang X; Zhang C; Zhang H
bioRxiv; 2023 May; ():. PubMed ID: 37398114
[TBL] [Abstract][Full Text] [Related]
11. SNS-032 attenuates liver fibrosis by anti-active hepatic stellate cells
He XL; Hu YH; Chen JM; Zhang DQ; Yang HL; Zhang LZ; Mu YP; Zhang H; Chen GF; Liu W; Liu P
Front Pharmacol; 2022; 13():1016552. PubMed ID: 36313366
[TBL] [Abstract][Full Text] [Related]
12. Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.
Zabihi M; Lotfi R; Yousefi AM; Bashash D
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1585-1606. PubMed ID: 35781526
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions.
Juric V; Murphy B
Cancer Drug Resist; 2020; 3(1):48-62. PubMed ID: 35582046
[TBL] [Abstract][Full Text] [Related]
14. Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer.
Constantin TA; Greenland KK; Varela-Carver A; Bevan CL
Oncogene; 2022 Jun; 41(24):3303-3315. PubMed ID: 35568739
[TBL] [Abstract][Full Text] [Related]
15. The Renaissance of Cyclin Dependent Kinase Inhibitors.
Ettl T; Schulz D; Bauer RJ
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053461
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.
Gregory GP; Kumar S; Wang D; Mahadevan D; Walker P; Wagner-Johnston N; Escobar C; Bannerji R; Bhutani D; Chang J; Hernandez-Ilizaliturri FJ; Klein A; Pagel JM; Rybka W; Yee AJ; Mohrbacher A; Huang M; Farooqui M; Marinello P; Quach H
Blood Adv; 2022 Feb; 6(4):1232-1242. PubMed ID: 34972202
[TBL] [Abstract][Full Text] [Related]
17. Polyphyllin I, a lethal partner of Palbociclib, suppresses non-small cell lung cancer through activation of p21/CDK2/Rb pathway
Shen Z; Wang J; Ke K; Chen R; Zuo A; Zhang R; Wan W; Xie X; Li X; Song N; Fu H; Zhang Z; Cai E; Shen J; Zhang Q; Shi X
Cell Cycle; 2021 Dec; 20(23):2494-2506. PubMed ID: 34658297
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
Susanti NMP; Tjahjono DH
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
[TBL] [Abstract][Full Text] [Related]
19. The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time.
Ono M; Oba T; Shibata T; Ito KI
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3211-3224. PubMed ID: 34244855
[TBL] [Abstract][Full Text] [Related]
20. Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.
Yao JY; Xu S; Sun YN; Xu Y; Guo QL; Wei LB
Acta Pharmacol Sin; 2022 Apr; 43(4):1033-1045. PubMed ID: 34188177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
